Five organizations subordinate to the Ministry of Health will be able to issue permits for gender reassignment operations in children in the presence of congenital anomalies and genetic and endocrine diseases. About it it says in the draft government resolution developed by the Russian Ministry of Health.
The draft resolution proposes to approve five medical organizations, “by decision of the medical commissions of which medical interventions related to the treatment of congenital anomalies (malformations), genetic and endocrine diseases associated with impaired formation of the genital organs in children are allowed.” Institutions will also issue a medical certificate “on the correspondence of sexual characteristics to the characteristics of a particular gender, as well as the form and procedure for issuing such decisions and medical reports,” the document says.
The following organizations will issue permits for gender reassignment:
The document also approves the procedure for issuing decisions of medical commissions on the admissibility of medical interventions. Such a commission will necessarily include an obstetrician-gynecologist, a geneticist, a pediatric urologist-andrologist, a pediatric endocrinologist, a pediatrician, a child psychiatrist and a medical psychologist.
The resolution, if adopted, will come into force on March 1, 2024. This period, as stated in the explanatory note to the document, is due to “the need to inform medical organizations of the Russian Federation of all forms of ownership about the approved list of federal medical organizations, forms and procedures for issuing decisions and medical reports by doctors commissions of federal medical organizations included in the specified list.”
Russian President Vladimir Putin in July signed law banning gender reassignment in Russia. The changes establish a ban on surgical operations and hormonal therapy, as well as on any other medical interventions aimed at developing primary or secondary sexual characteristics of a different sex in a person. It was reported that the exceptions would apply to medical interventions related to the treatment of congenital anomalies, genetic and endocrine diseases associated with impaired formation of the genital organs in children.